Somatostatin receptor in human hepatocellular carcinomas: Biological, patient and tumor characteristics

Digestive Surgery

Volumn 25, Issue 1, 2008, Pages 21-26

  Verhoef, C ^a   Van Dekken, H ^a   Hofland, L J ^a   Zondervan, P E ^a   De Wilt, J H W ^a   Van Marion, R ^a   De Man, R A ^a   Ijzermans, J N M ^a   Van Eijck, C H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical characteristics; Genetic alterations; Hepatocellular carcinoma; Somatostatin receptor

Indexed keywords

ALPHA FETOPROTEIN; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CELL PROLIFERATION; CHROMOSOME 1; CLINICAL ARTICLE; CORRELATION ANALYSIS; DNA PROBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENDER; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER DISEASE; MALE; PLOIDY; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, SOMATOSTATIN;

EID: 42449152946     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000117819     Document Type: Article

References (35)

1. El-Serag H, Davilla JA, Petersen NJ, McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823.
2. Verhoef C, Visser O, de Man RA, de Wilt JHW, Ijzermans JNM, Janssen-Heijnen MLGl: HCC in the Netherlands: incidence treatment and survival patterns. EJC 2004;40:1530-1538.
3. Schwartz JD, Beutler AS: Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials. II. systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs 2004;15:439-452.
4. Yuen MF, Poon RT, Lai CL, et al: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2003;36:687-691.
5. Rabe C, Pilz T, Allgaier, et al: Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide. Z Gastroenterol 2002;40:395-400.
6. Raderer M, Hejna MH, Muller C, et al: Treatment of hepatocellular cancer with the long acting somatostatin analoglanreotide in vitro and in vivo. Int J Oncol 2000;16:1197-1201.
7. Dimitrouloupoulos D, Xinopoulos D, Tsamakidis K, et al: The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 2002;49:1245-1250.
8. Samonakis DN, Moschandreas J, Arnaoutis T, et al: Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 2002;9:903-907.
9. Gibson JB, Sobin LH: Histological typing of tumours of the liver, biliary tract and pancreas; in International Histological Classification of Tumours. Geneva, World Health Organisation, 1978.
10. Edmondson HA, Steiner PE: Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
11. Alers JC, Van Dekken H: Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization. Progr Histochem 1996;31:1-137.
12. Van Dekken, Wink J, Alers JC, de Man RA, Ijzermans JN, Zondervan PE: Genetic evaluation of the dysplasia-carcinoma sequence in chronic viral liver disease: a detailed analysis of two cases and a review of the literature. Acta Histochem 2003:105:29-41.
13. Van Dekken H, Verhoef C, Wink J, van Marion R, Vissers KJ, Hop WC, de Man RA, Ijzermans JN, van Eijck CHJ, Zondervan PE: Cell biological evaluation of liver cell carcinoma, dysplasia and adenoma by tissue micro-array analysis. Acta Histochem 2005:107:161-171.
14. Hofland L, et al: Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 1999;84:775-780.
15. Korner M, et al: Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol 2005;29:1642-1651.
16. Schally AV: Oncological applications of somatostatin analogues. Cancer Res 1988;48:6977-6985.
17. Lamberts SW, Krenning EP, Reubi JC: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450-482.
18. Weckbecker G, Raulf F, Stolz B, Bruns C: Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993;60:245-264.
19. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON: Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-447.
20. Allgaier HP, Becker G, Olschewski M, et al: Octreotide treatment in patients with advanced hepatocellular carcinoma: first results of the randomized placebo-controlled double blind Hector trial. Hepatology 2003;38:760A.
21. Bläker M, Schmitz M, Gocht A, et al: Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 2004;41:112-118.
22. Reubi JC, Zimmerman A, Jonas S, Waser B, Neuhaus P, Laederach U, Wiedenmann B: Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999;45:766-774.
23. Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P, Chaudhari S: Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 2005;92:175-186.
24. Reynaert H, Rombouts K, Vandermonde A, et al: Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004;53:1180-1189.
25. Reubi JC: Octreotide and nonendocrine tumors. Basic knowledge and therapeutic potential; in Lomax P, Scarpignato C, Vessel E (eds): Octreotide from Basic Science to Clinical Medicine. Basel, Karger, 1996, pp 246-269.
26. Reubi JC, Laissue J, Krenning E, Lamberts SW: Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992;43:27-35.
27. Zhang CY, Yokogoshi Y, Yoshimoto K, Fujinaka Y, Matsumoto K, Saito S: Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103. Biochem Biophys Res Commun 1995;210:805-815.
28. Hsu HC, Tseng HJ, Lai PL, et al: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumour growth and invasiveness. Cancer Res 1993;53:4691-4694.
29. Hsu HC, Peng SY, Lai PL, et al: Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis: a study of 138 patients with unifocal HCC. Int J Oncol 1994;4:1341-1347.
30. Peng SY, Chen WJ, Lai PL, et al: High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and β-catenin. Int J Cancer 2004;112:44-50.
31. Qin LX, Tang ZY, Ma ZC, et al: p53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol 2002;8:459-463.
32. Sherr CJ: Cancer cell cycles. Science 1996;274:1672-1677.
33. Baek MJ, Piao Z, Kim NG, et al: P16 is a major inactivation target in hepatocellular carcinoma. Cancer 2000;89:60-68.
34. Matsuda Y, Ichida T, Genda T, et al: Loss of p16 contributes to p27 sequestration by cyclin D1-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res 2003;9:3389-3396.
35. Edamoto Y, Hara A, Biernat W, et al: Alterations of RB1, p53 and Wnt pathways in hepatocellulular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003;106:334-341.